Navigation Links
Preclinical Study Presented at AACR Annual Meeting Shows Peregrine's Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
Date:4/15/2008

e response or disease stabilization in 50% of the evaluable patients. Peregrine has received regulatory approval to conduct three Phase II trials to study the anti-tumor effects of bavituximab in combination with chemotherapy. These include two breast cancer protocols and a non-small cell lung cancer protocol. One of the bavituximab breast cancer trials is currently enrolling and dosing patients and the two other trials are expected to begin shortly. Bavituximab is in clinical trials in the U.S. in patients with advanced solid tumors and in patients co-infected with HCV and HIV.

No. 2841: Xianming Huang, Dan Ye, Philip E. Thorpe. An immunocytokine that binds to phosphatidylserine generates an effective cell-based tumor vaccine in mice, UT Southwestern Medical Ctr., Dallas, TX, April 14, 2008, 1:00 PM - 4:00 PM PDT

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigatio
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Preclinical Study Shows CTIs Brostallicins Cancer-Killing Ability Based on Genetic Profiling
2. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
3. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
4. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
5. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
6. Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
7. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
8. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
9. Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
10. Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences
11. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014  A Boston Scientific Corporation (NYSE: ... stent removability and preliminary long term stricture resolution ... the August issue of the peer-reviewed journal, Gastroenterology. ... is being conducted in 11 countries and five ... metal stents (FCSEMS) after extended indwell (i.e., up ...
(Date:8/29/2014)... -- Thoratec Corporation (NASDAQ: THOR ), a ... save, support and restore failing hearts, said today it ... Healthcare Conference on Wednesday, September 10. ... will provide an update on the company, beginning at ... Time).   A webcast of the presentation ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... Peptide Cancer Therapeutics Market & Pipeline Insight 2014" ... methods developed to prevent and eradicate the prevalence of ... methods are confined to low specificity, safety and large ... look for a better solution. It has been discovered ...
Breaking Medicine Technology:Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2
... effectiveness for, patients, but Gilead Sciences and Merck and Co. ... ... LOS ANGELES, Sept. 10 AIDS Healthcare,Foundation (AHF) today called ... three-in-one, once daily lifesaving HIV,treatment, Atripla, in developing countries. When ...
... BioMosaics Inc., a cancer,biomarker development company, announced today ... products for the identification of Glypican-3,(GPC3) in human ... tests. This will,allow the GPC3 (Human Glypican-3) ELISA ... and the GPC3 (Human Glypican-3) Monoclonal Antibody (clone,1G12) ...
Cached Medicine Technology:Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations 2Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations 3BioMosaics' Glypican-3 Blood & Tissue Tests Receive CE Marking in Europe 2
(Date:9/1/2014)... September 02, 2014 NAPW ... Healthcare, LLC as a 2014 Professional Woman of the ... for leadership in office management. As the largest, most-recognized ... virtually every industry and profession, the National Association of ... over 600,000 members and nearly 300 Local Chapters. , ...
(Date:9/1/2014)... NAPW honors ... Orthopedics Pain Treatment & Cardiology, as a ... is recognized with this prestigious distinction for leadership ... organization of women in the country, spanning virtually ... Professional Women is a powerfully vibrant networking community ...
(Date:9/1/2014)... (PRWEB) September 02, 2014 Spine Team ... annual Reader’s Choice ‘Best of 2014’ award based on ... Northeast Tarrant County, Las Colinas & Coppell, Rockwall & ... would like to thank our patients and the residents ... Texas as LIVING magazine’s ‘Best of 2014’ in the ...
(Date:9/1/2014)... an innovative Washington State University study of deadly force ... black people. But when it came time to shoot, ... longer to pull the trigger against them than against ... the recent Journal of Experimental Criminology , grow ... disproportionate number of ethnic and racial minorities shot by ...
(Date:9/1/2014)... UWDress.com, a well-known wedding dress manufacturer and ... green bridesmaid dresses for its new and old ... company’s online category. What’s more, they are offered at ... offer is specially launched to celebrate the coming of ... have won great appreciation from worldwide clients. Now, the ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Announces Victoria Smith, Office Manager at Apex Healthcare, LLC, a 2014 Professional Woman of the Year 2Health News:National Association of Professional Women Announces Laura Brinkley, Manager, Gibson Orthopedics Pain Treatment & Cardiology Clinic, a 2014 Professional Woman of the Year 2Health News:Spine Team Texas chosen in LIVING Magazine’s Reader’s Choice Awards 2Health News:WSU 'deadly force' lab finds racial disparities in shootings 2Health News:WSU 'deadly force' lab finds racial disparities in shootings 3Health News:2014 Lime Green Bridesmaid Dresses Offered At UWDress.com 2
... could help keep ones mind working.The study also found those ... fat have an increased risk of cognitive impairment during middle ... eat could play a role in your risk for dementia. ... with a lower risk of dementia. Researchers in the Netherlands ...
... in the recent issue of British Medical Journal say ... suicides and suicidal attempts.// ,Depression is characterized ... activities, low levels of self-esteem and confidence, and in ... and suicide. ,Clinical depression, also known as ...
... thyroid problem may have a lower risk of developing ... have shown that one of the circulating thyroid hormones ... mammary gland cells responded to thyroid hormones , population ... thyroid hormone and breast cancer. ,In a recent ...
... recent study researchers suggest that women drink wine to keep their ... wine is good for the heart. Although much of the research ... men, it is still not clear why moderate amounts of wine ... effects of wine on women’s hearts, the alcohol habits of 102 ...
... research conducted by Northwestern University about the effects of epidural ... analgesic given at the early stages of labor does not ... in their final term were observed for the study. All ... women who were given epidural in the early stages of ...
... onset wheezing is associated with high levels of allergies, ... the longest duration of wheezing also appear to have ... later in childhood end up with the same characteristics ... involved nearly 1,500 children born on the Isle of ...
Cached Medicine News:
A standard, durable and reliable indirect....
Designed to retain the desired curve during oral intubation....
Facilitates intubation of tracheal tubes....
SunGlide™ Stylette - Blue Neonatal. Use in 2.0 to 3.5mm tubes. 25/box....
Medicine Products: